These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 21124035)
1. Castration refractory prostate cancer: cinderella finally comes to the ball. Chowdhury S; Harper P; Powles T Onkologie; 2010; 33(12):655-6. PubMed ID: 21124035 [No Abstract] [Full Text] [Related]
2. [Castration resistant prostate cancer 2011]. Miller K Aktuelle Urol; 2011 Mar; 42(2):95-102. PubMed ID: 21437832 [TBL] [Abstract][Full Text] [Related]
3. Innovations in the systemic therapy of prostate cancer. Shepard DR; Raghavan D Nat Rev Clin Oncol; 2010 Jan; 7(1):13-21. PubMed ID: 19997075 [TBL] [Abstract][Full Text] [Related]
4. [New treatments for castration-resistant prostate cancer]. Sautois B; Gennigens C Rev Med Liege; 2013 Feb; 68(2):94-6. PubMed ID: 23469490 [TBL] [Abstract][Full Text] [Related]
5. New treatment options for castration-resistant prostate cancer. Simondsen K; Kolesar J Am J Health Syst Pharm; 2013 May; 70(10):856-65. PubMed ID: 23640346 [TBL] [Abstract][Full Text] [Related]
6. Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer. Pal SK; Sartor O Maturitas; 2011 Feb; 68(2):103-5. PubMed ID: 21093995 [TBL] [Abstract][Full Text] [Related]
7. Novel and bone-targeted agents for CRPC. Fizazi K; Albiges L; Massard C; Escudier B; Loriot Y Ann Oncol; 2012 Sep; 23 Suppl 10():x264-7. PubMed ID: 22987974 [TBL] [Abstract][Full Text] [Related]
8. [Promising on advanced cancer, several new drugs coming]. Widmark A; Karlsson CT Lakartidningen; 2012 Feb 22-28; 109(8):416-9. PubMed ID: 22509668 [No Abstract] [Full Text] [Related]
9. Recent advances in the therapy of castration-resistant prostate cancer: the price of progress. Vasani D; Josephson DY; Carmichael C; Sartor O; Pal SK Maturitas; 2011 Oct; 70(2):194-6. PubMed ID: 21831545 [TBL] [Abstract][Full Text] [Related]
10. [Managing side effects of androgene deprivation in prostate cancer]. Thalgott M; Gschwend JE; Retz M MMW Fortschr Med; 2010 Oct; 152(41):40-3. PubMed ID: 21090376 [No Abstract] [Full Text] [Related]
11. New treatment options for patients with metastatic castration-resistant prostate cancer. Higano CS Cancer Treat Rev; 2012 Aug; 38(5):340-5. PubMed ID: 21944872 [TBL] [Abstract][Full Text] [Related]
15. Cabazitaxel in prostate cancer: stretching a string. Dorff TB; Quinn DI Lancet; 2010 Oct; 376(9747):1119-20. PubMed ID: 20888974 [No Abstract] [Full Text] [Related]
16. How should we understand the term androgen deprivation therapy? Drewa T; Soloway MS Eur Urol; 2012 Apr; 61(4):856. PubMed ID: 22266269 [No Abstract] [Full Text] [Related]
17. Agents that target androgen synthesis in castration-resistant prostate cancer. Ferraldeschi R; de Bono J Cancer J; 2013; 19(1):34-42. PubMed ID: 23337755 [TBL] [Abstract][Full Text] [Related]
18. New agents in the arsenal to fight castrate-resistant prostate cancer. Ezzell EE; Chang KS; George BJ Curr Oncol Rep; 2013 Jun; 15(3):239-48. PubMed ID: 23440553 [TBL] [Abstract][Full Text] [Related]
19. [Hormonal treatment of cancer of the prostate: review and present status]. Ganzer R; Wieland WF; Bach T; Rössler W; Blana A Dtsch Med Wochenschr; 2007 Jan; 132(4):161-6. PubMed ID: 17230333 [No Abstract] [Full Text] [Related]
20. Novel chemotherapies in development for management of castration-resistant prostate cancer. Tewari AK; George DJ Curr Opin Urol; 2013 May; 23(3):220-9. PubMed ID: 23511791 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]